UK regen med inquiry to flesh out R&D funding and reimbursement barriers
This article was originally published in Clinica
Executive Summary
Regenerative medtech firms have a major opportunity to contribute to UK policy-making in this field, through a far-reaching parliamentary inquiry that promises to investigate current barriers to R&D funding and commercialisation, among other key industrial and regulatory considerations.